The Russell's U.S. indexes
annually captures the
4,000 largest U.S. stocks
EnteroMedics, the creator of medical devices using neuroblocking technology, which addresses obesity and other gastrointestinal disorders, has been added to the Russell 3000(R) Index.
The Russell's U.S. index annually captures the 4,000 largest U.S. stocks, ranking them by total market capitalization.
EnteroMedics' membership in the Russell 3000 will remain effective for a year and means that it has automatic inclusion in the small-cap Russell 2000 Index and relevant growth and value indexes. An industry-leading $4 trillion in assets are currently benchmarked to the Russell indexes.
Ad Statistics
Times Displayed: 113476
Times Visited: 6766 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
About EnteroMedics Inc.
EnteroMedics is a development stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity and other gastrointestinal disorders.
EnteroMedics' proprietary neuroblocking technology, VBLOC(R) vagal blocking therapy, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. EnteroMedics has met its enrollment goal under an FDA-approved Investigational Device Exemption (IDE) for the EMPOWER(TM) Study using the Maestro(R) System, its initial product for the treatment of obesity. EnteroMedics is currently recruiting patients outside of the United States for a feasibility study examining VBLOC Therapy's effects on blood glucose levels in diabetic patients. For more information, visit www.enteromedics.com
